At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
Proton therapy +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility and Phase 1/II Trial of Adjuvant Radiation Therapy for the Treatment of Urothelial Bladder Cancer Using Proton Therapy or IMRT
In Brief
A Phase 2 clinical trial evaluating Proton therapy and IMRT for Urothelial Carcinoma of the Bladder. Completed, enrolled 2 participants across 1 site.
Detailed Summary
Invasive urothelial bladder cancer is a common malignancy causing 14,000 deaths annually in the United States. The primary objective of the feasibility/Phase I portion of the study is to establish the feasibility and safety of proton and the safety of IMRT for patients with pure or mixed variant urothelial carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma of the Bladder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedJan 2012
Primary CompletionDec 2013
TodayJul 2026
First PostedJan 27, 2012
Enrollment StartJan 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.4 years ago
Interventions
Proton therapyradiation
IMRTradiation